Saba Capital Management, L.P. sold $906k of HQL
owner at abrdn Life Sciences Investors. 64,536 shares at an average of $14.04, traded Sep 17, 2025, filed Sep 19, 2025.
Score components
- +12Role10% owner
- +24Trade size$906k at market
- 0Share of holdings soldSold 2.2% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +17.2%, 3m +23.6%, 6m +22.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001510281-25-000492, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 17, 2025 | SOpen-market sale Common Stockindirect: - | -24,328 | $13.99 | $340k | 2,926,453 | Sep 19, 2025 |
| Sep 18, 2025 | SOpen-market sale Common Stockindirect: - | -40,208 | $14.07 | $566k | 2,886,245 | Sep 19, 2025 |
Related signals
Other insiders at abrdn Life Sciences Investors and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HQLbuy abrdn Life Sciences Investors | Chris LaVictoire Mahai director | $10k 527 shares | - | |
| 34Weak | HQLbuy abrdn Life Sciences Investors | Christian Pittard director | $134k 7,923 shares | - | |
| 33Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $687k 48,612 shares | -2% | |
| 18Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $38k 2,726 shares | -0% | |
| 24Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $216k 15,116 shares | -1% | |
| 24Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $198k 14,083 shares | -0% | |
| 27Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $330k 23,723 shares | -1% | |
| 12Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $5,532 400 shares | -0% | |
| 23Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $151k 10,710 shares | -0% | |
| 23Weak | HQLsell abrdn Life Sciences Investors | Saba Capital Management, L.P. owner | $145k 11,419 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.